Intra-Cellular Therapies (ITCI) 8-K Intra-cellular Therapies Reports Fourth Quarter and Full-year 2018 Financial Results and Provides Corporate Update

Exhibit 99.1

INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK, February 27, 2019 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2018, and provided a corporate update.

“2018 was an important year for ITCI,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “The FDA accepted for review our NDA for lumateperone for the treatment of schizophrenia. We also made significant progress in building our commercial infrastructure in preparation for potential launch, including the hiring of our commercial senior leadership team. In addition, we continued to advance our clinical and preclinical development programs including lumateperone for bipolar depression,ITI-214 andITI-333 and look forward to providing additional updates on these programs in the year ahead.”

Corporate Update

Lumateperone Programs

Schizophrenia

• Our new drug application (NDA) for lumateperone, an investigational agent for the treatment of schizophrenia, is under review by the U.S. Food and Drug Administration (FDA). The PDUFA target action date is September 27, 2019.

• We continue to expand our infrastructure to support the commercialization of lumateperone, pending FDA approval. In the fourth quarter of 2018, we appointed Mark Neumann as Executive Vice President, Chief Commercial Officer. Mark has extensive marketing and sales experience in various therapeutic areas, including neuroscience and cardiology. In addition, we have continued to expand our commercial leadership team and have now hired senior leaders across all the key commercial functions.

• As our clinical programs have advanced, we have supplemented our clinical development expertise with additional senior team members. Last year, we appointed Dr. Suresh

1

Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs, and Dr. Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs. Both have extensive experience in bringing neuropsychiatric products through late stage clinical development and regulatory approval. They join Dr. Andrew Satlin, our Chief Medical Officer, and Dr. Kimberly Vanover, our Senior Vice President of Early Stage Clinical Development and Translational Medicine, to lead our clinical team.

• Favorable safety data from our lumateperone open-label safety switching study (Study 303) in patients with stable symptoms of schizophrenia were replicated and extended from short-term to long-term exposure. This second part of the study enrolled 603 patients for up to one year of treatment with lumateperone after a switch fromstandard-of-care (SOC) antipsychotic therapy. We analyzed data from over 300 patients who completed at least six months of treatment and over 100 patients who completed one year of treatment, meeting ICH criteria for long-term safety evaluation. The results demonstrated that lumateperone was generally well tolerated and exhibited statistically significant improvements from baseline on key safety measures of body weight and cardiometabolic and endocrine parameters, without motor side effects often associated with other antipsychotic medications. In contrast to many other antipsychotics that cause weight gain, mean body weight significantly decreased at six months(-1.82 kg at Day 175, p < 0.001) and one year(-3.16 kg at Day 350, p < 0.001) of treatment with lumateperone after switch from SOC antipsychotic treatment. Of the 603 patients in the study, 24% experienced a decrease of³ 7% from their SOC baseline body weight over the course of the study, whereas only 8% experienced a body weight increase of³7%. The favorable cardiometabolic and endocrine safety profile seen in short-term studies of lumateperone persisted over aone-year duration of treatment, with statistically significant (p < 0.001) reductions from SOC baseline in total cholesterol, LDL cholesterol and prolactin and stable blood levels of glucose, insulin, and HDL cholesterol. There were no signs of treatment-emergent extrapyramidal side effects, akathisia, or dyskinesia. We plan to present further analyses from this study at medical meetings later this year.

Bipolar Depression

• We continue to advance our lumateperone bipolar depression Phase 3 clinical program. This program consists of two monotherapy studies and one adjunctive study. We have completed patient enrollment in both monotherapy studies: Study 401 conducted in the U.S. and Study 404 conducted globally. We anticipate reporting topline results from Study 401 and Study 404 simultaneously in the second quarter of 2019. Subject to the outcome of these trials, we expect to submit for FDA regulatory approval of lumateperone for bipolar depression in the second half of 2019.

Major Depressive Disorder

• We believe lumateperone has the potential to exhibit potent and rapid antidepressant effects and have commenced a program in major depressive disorder (MDD), beginning

2

with a dose-finding trial. In order to explore the effect of different modes of drug administration and the potential for rapid-onset antidepressant activity, our program includes the assessment of novel formulations of lumateperone. Pharmacokinetic studies evaluating these formulations of lumateperone are currently ongoing.

• We have presented preclinical data demonstrating lumateperone’s potential as an antidepressant and the molecular pharmacology consistent with a rapid acting profile. Lumateperone, as a standalone agent, indirectly enhances glutamatergic neurotransmission through both AMPA and NMDA channels in the prefrontal cortex. Additionally, we presented data demonstrating that lumateperone increases protein phosphorylation of key proteins in the mTOR pathway. These findings, in addition to the potent SERT activity previously described with lumateperone and the improvement in depressive symptoms found in patients with schizophrenia andco-morbid depression, suggest the potential for lumateperone to exhibit potent and rapid antidepressant effects.

ITI-214 (PDE1 inhibitor) Programs

Parkinson’s Disease

• Last year, we presentedtop-line results from our Phase 1/2 randomized, double-blind, placebo-controlled, multiple ascending dose clinical trial to evaluateITI-214 in patients withmild-to-moderate Parkinson’s disease (PD). The primary objective was to evaluate safety and tolerability. Efficacy in improving motor andnon-motor symptoms of PD was explored using multiple scales, providing input from both subjects and site raters. Topline results demonstrateITI-214 was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. No serious adverse events were reported in the trial, and no clinically significant effects ofITI-214 compared to placebo were observed on vital signs, or cardiovascular or laboratory parameters.

• This year, we plan to advance our PD program with a Phase 2,proof-of-concept clinical trial ofITI-214, our phosphodiesterase 1 (PDE1) inhibitor, for the treatment of PD.

Heart Failure

• Data from preclinical models of heart failure, published last year in the journalCirculation, indicateITI-214 acts by a novel mechanism of action via modulation of the adenosine A2B receptor signaling pathway and increases cardiac contractility without increasing intracellular calcium. The pharmacological profile ofITI-214 introduces a new mechanism of action for the treatment of heart failure that is different from ß-adrenergic agonism and PDE3 inhibition and that may provide an effective and safer alternative to existing therapies.

3

• We initiated ourITI-214 clinical program for the treatment of heart failure. A randomized, double-blind, placebo-controlled study of escalating single doses ofITI-214 to evaluate hemodynamic effects and safety in patients with systolic heart failure is ongoing. Clinical conduct of the first dose cohort, which evaluatedITI-214 10 mg, is complete.ITI-214 was well tolerated and the safety profile supported advancement to the next cohort, which will evaluate 30 mg.

ITI-333 Program

• ITI-333, our novel, oral modulator of serotonin, dopamine, and mu opioid receptors, continues to advance in preclinical development. In preclinical models of acute and inflammatory pain,ITI-333 exhibits potent analgesia but is not associated with dependence or abuse liability, effects commonly associated with opioiduse. ITI-333 also dose-dependently reduces symptoms associated with naloxone-precipitated opioid withdrawal and suppressescue-induced heroin reinstatement responding, models predictive of relapse behavior, at doses that do not decrease gastrointestinal motility or depress respiratory function. We plan to developITI-333 for the treatment of opioid and other substance use disorders, pain, and mood disorders. We expect to initiate our clinical program later this year.

Selected Fourth Quarter and Year End 2018 Financial Results

Intra-Cellular Therapies (the Company or ITCI) reported a net loss of $40.7 million, or $0.75 per share (basic and diluted), for the fourth quarter of 2018 compared to a net loss of $30.2 million, or $0.56 per share (basic and diluted), for the fourth quarter of 2017. The Company reported a net loss of $155.1 million, or $2.84 per share (basic and diluted), for the full year ended December 31, 2018 compared with a net loss of $97.8 million, or $2.12 per share (basic and diluted), for the full year ended December 31, 2017.

Research and development (R&D) expenses for the fourth quarter of 2018 were $33.6 million, compared to $26.9 million for the fourth quarter of 2017. The $6.7 million increase is primarily due to higher clinical andnon-clinical related costs for lumateperone, manufacturing costs and labor costs in the fourth quarter of 2018. Research and development expenses for the year ended December 31, 2018 were $132.2 million, compared to $79.4 million for the year ended December 31, 2017. The $52.8 million increase is primarily due to higher clinical andnon-clinical related costs for lumateperone, manufacturing costs and labor costs in addition to other nonITI-007 related projects.

General and administrative (G&A) expenses were $9.0 million for the fourth quarter of 2018, compared to $5.8 million for the same period in 2017. The increase of $3.2 million is due primarily to increases in precommercialization costs, labor costs and stock compensation expense. General and administrative expenses for the year ended December 31, 2018 were $30.1 million, compared to $23.7 million for the year ended December 31, 2017. The increase of $6.4 million is primarily due to increases in precommercialization costs, labor costs, and stock compensation expense.

4

Cash, cash equivalents and investment securities totaled $347.5 million at December 31, 2018, compared to $464.3 million at December 31, 2017.

We expect total spend for 2019 to range between $225 to $240 million. We expect these funds will be used primarily forpre-commercialization preparation, initial commercialization activities and related infrastructure expansion in connection with the commercialization of lumateperone, if approved, for the treatment of schizophrenia; the development of lumateperone in our late stage clinical programs; the development of our other product candidates, includingITI-214; the continuation of manufacturing activities in connection with the development of lumateperone; and general operations. We anticipate the $347.5 million of existing cash, cash equivalents and investment securities as of December 31, 2018 will fund our operations into the second half of 2020.

Conference Call and Webcast Details

The Company will host a live conference call and webcast today at 8:30 AM Eastern Time to discuss the Company’s financial results and provide a corporate update. The live webcast and subsequent replay may be accessed by visiting the Company’s website at www.intracellulartherapies.com. Please connect to the Company’s website at least5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call1-(844)835-6563 (U.S.) or1-(970)315-3916 (international) to listen to the live conference call. The conference ID number for the live call is 8789239. Please dial in approximately 10 minutes prior to the call.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The Company is developing its lead drug candidate, lumateperone (also known asITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. Lumateperone is under review by the FDA for the treatment of schizophrenia and is in Phase 3 clinical development for the treatment of bipolar depression. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company’s PDE1 portfolio,ITI-214, is in development for the treatment of symptoms associated with Parkinson’s disease and for the treatment of heart failure.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements

5

include statements regarding, among other things, our expected use of our cash, cash equivalents and investment securities; our beliefs about the extent to which the results of our clinical trials to date support our NDA submission for lumateperone for the treatment of schizophrenia; our plans and the expected timing for the availability and reporting of data from our ongoing Phase 3 trials in bipolar depression, and our expectations about the timing of our NDA submission for bipolar depression; our expectations about presenting data at upcoming scientific and medical conferences; our development plans for our PDE program, includingITI-214 and our expected timing of the initiation of additional clinical trials forITI-214; the potential forITI-214 to provide an effective and safer alternative to existing therapies; our development plans for ourITI-333 program and our expected timing of the initiation of clinical trials forITI-333 and development efforts and plans under the caption “About Intra-Cellular Therapies.” All such forward-looking statements are based on management’s present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the following: whether the NDA for lumateperone for the treatment of schizophrenia will be approved by the FDA; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with lumateperone in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Lisa Burns

agray@burnsmc.com

212-213-0006

6

MEDIA INQUIRIES:

Patrick Ryan, Esq.

Corporate Media Relations, W2Owcg

pryan@wcgworld.com

7

INTRA-CELLULAR THERAPIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended December 31,						Year Ended December 31,
	2018			2017			2018(1)			2017(1)
	(Unaudited)			(Unaudited)			(Unaudited)			(Audited)
Revenues	$	—		$	5,055		$	—		$	245,837
Costs and expenses:
Research and development		33,605,629			26,929,041			132,166,913			79,419,009
General and administrative		9,017,311			5,784,278			30,099,855			23,666,957
Total costs and expenses		42,622,940			32,713,319			162,266,768			103,085,966
Loss from operations		(42,622,940	)		(32,708,264	)		(162,266,768	)		(102,840,129	)
Interest income		(1,874,904	)		(1,441,117	)		(7,140,957	)		(4,005,864	)
Income tax (benefit) expense		—			(1,058,435	)		1,600			(1,060,851	)
Net loss	$	(40,748,036	)	$	(30,208,712	)	$	(155,127,411	)	$	(97,773,414	)
Net loss per common share:
Basic & Diluted	$	(0.75	)	$	(0.56	)	$	(2.84	)	$	(2.12	)
Weighted average number of common shares:
Basic & Diluted		54,750,566			54,407,104			54,707,865			46,181,926

(1) The condensed consolidated statements of operations for the years ended December 31, 2018 and 2017 have been derived from the financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

8

INTRA-CELLULAR THERAPIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2018 (1)			December 31, 2017 (1)
	(Unaudited)			(Audited)
Assets
Current assets:
Cash and cash equivalents	$	54,947,502		$	37,790,114
Investment securities,available-for-sale		292,583,046			426,540,921
Prepaid expenses and other current assets		7,908,133			4,884,293
Total current assets		355,438,681			469,215,328
Property and equipment, net		1,159,766			1,137,171
Long term deferred tax asset, net		529,218			1,058,435
Other assets		78,833			75,765
Total assets	$	357,206,498		$	471,486,699
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		13,961,060			6,173,539
Accrued and other current liabilities		20,044,866			6,424,221
Accrued employee benefits		2,293,259			1,611,846
Total current liabilities		36,299,185			14,209,606
Long-term deferred rent		3,192,432			2,840,132
Total liabilities		39,491,617			17,049,738
Stockholders’ equity:
Common stock, $0.0001 par value: 100,000,000 shares authorized; 54,895,295 and 54,597,679 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively		5,490			5,460
Additionalpaid-in capital		880,753,339			862,479,505
Accumulated deficit		(562,376,191	)		(407,248,780	)
Accumulated comprehensive loss		(667,757	)		(799,224	)
Total stockholders’ equity		317,714,881			454,436,961
Total liabilities and stockholders’ equity	$	357,206,498		$	471,486,699

(1) The condensed consolidated balance sheets at December 31, 2018 and 2017 have been derived from the financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

9